TLN-372

DRUG2 trials

Sponsors

Treeline Biosciences Inc., Treeline Biosciences, Inc.

Conditions

KRAS Mutant Solid TumorsLocally advanced or metastatic solid tumors

Phase 1

TLN-372 in Advanced KRAS Mutant Solid Tumors

RecruitingNCT07204340

Treeline Biosciences, Inc.KRAS Mutant Solid Tumors

Start: 2025-09-29End: 2032-04-01Target: 240Updated: 2026-02-27

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination with Other Anti-Tumor Agents, in Patients with Advanced KRAS Mutant Solid Tumors

Not yet recruitingCTIS2025-523086-22-00

Treeline Biosciences Inc.Locally advanced or metastatic solid tumors

Target: 20Updated: 2026-01-07